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ABSTRACT 
Background: Cutaneous leishmaniasis (CL) is a disease of public health importance in Nigeria, with high prevalence 
in the Northwest and Northeastern part of the country. The side effects of antimonial drugs {stibogluconate (SSG) and 
meglumine antimoniate} in the treatment of CL have often resulted in poor drug adherence and default by patients 
and possible drug resistance. The increasing default to follow-up and the significant side effects associated with 
antimonial therapy necessitated the dire need of alternative therapeutic modalities. Thus, this study aimed at 
comparing the efficacy of topical silver nitrate with the antimonial drugs in the treatment of CL. 
Methods: A total of 95 patients with clinically diagnosed leishmaniasis and parasitologically proven CL participated 
in the study after their informed-consent had been obtained. The treatment selection was optional to the participants. 
Sixty (63.2%) patients received alternative therapy of topical silver nitrate as a single dose while 35(36.8%) patients 
received antimonial therapy for 21 days at 20mg/kg body weight.  
Results: On day 30 of treatment, 68 (86.1%) lesions among patients on topical silver nitrate healed completely as 
compared with only 5 (6.8%) among those on i.m. SSG. There was no improvement in 25 (34.2%) lesions among those 
on i.m. SSG compared with only 1 (1.2%) lesion among those on topical silver nitrate. Overall, there was a statistically 
significant difference in the cure rate among patients on silver nitrate as compared with those on i.m. SSG on the 21st 
and 30th days of treatment.(p<0.05). 
Conclusion: Topical silver nitrate therapy is an effective and better drug treatment for CL among this study 
population. 




Leishmaniasis is an infection that is caused by an 
obligate intracellular protozoa of the genus 
Leishmania; first described in 1903 by Leishman 
and Donovan. The natural transmission of  
 
Leishmania parasites is carried out by sandflies of 
the genus Phlebotomus or Lutzomyia (1). These 
parasites cause three forms of leishmaniasis  
according to the localization of the parasites in 
mammalian tissues, notably visceral, cutaneous, 
and mucosal leishmaniasis. The outcome of 
infection depends on the species of Leishmania 
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parasites and the host’s immune response (2). 
Visceral leishmaniasis (VL) is the most severe 
form of leishmaniasis involving internal organs 
such as the spleen and liver and is fatal if left 
untreated (3). 
Globally, about 350 million people live in areas of 
active transmission of Leishmania, with estimated 
14 million people directly affected in Africa, Asia, 
Europe, and America (4). The global burden of 
leishmaniasis has remained stable for some years, 
causing a morbidity and mortality loss of 2.4 
million Disability Adjusted Life-Years (DALYs) 
and approximately 70,000 deaths; a significantly 
high figure ranked among communicable 
diseases (5,6). Leishmaniasis and Human 
Immunodeficiency Virus (HIV) co-infection has 
surged as a major complication of leishmaniasis 
and has ignited calls for the recognition of 
leishmaniasis as an Acquired Immunodeficiency 
Syndrome (AIDS) defining-illness (7). In Africa, 
particularly Ethiopia and Sudan, it is estimated 
that 70% of adults with VL also have HIV 
infection (8).  
 
Northern Nigeria is one of the West African 
endemic CL foci, especially in Sokoto, Gusau, 
Katsina, Maiduguri and Azare9. Between 1924 
and 1941, the Nigeria health services recorded 
131 cases of CL and 5 cases of VL, but there was 
no indication that these cases were 
parasitologically confirmed. In 1942, smears of 14 
patients from Kano with cutaneous sores were 
confirmed parasitologically to be leishmaniasis. 
However, the first case of CL in Nigeria was 
officially reported in 1944 (9,10). In spite of the 
initial public health efforts on CL in this region, 
there is dearth of follow-up data on CL caused by 
Leishmania tropica and its treatment-induced cure 
rates.  
 
The current management of leishmaniasis are 
drug treatment of patients, to alleviate disease 
and vector control to reduce its transmission. 
Pentavalent antimonials (namely, sodium 
stibogluconate (SSG) and meglumine 
antimoniate) are the mainstay of anti-leishmanial 
therapy (11-13). However, the antimonials have 
serious adverse effects (such as pancreatitis, 
hepatotoxicity, and cardiotoxicity) when given 
intramuscularly (14,16) and are expensive (17). 
Moreover, the lengthy course of its 
administration and associated pain often results 
in low drug adherence, default and ultimately, 
drug resistance (18,18).  Bearing in mind several 
studies that have shown the high efficacy of 
colloidal silver as an antimicrobial (20,-23), the 
topical silver nitrate appears to be the most 
feasible alternative. Silver is toxic to 
microorganisms by poisoning respiratory 
enzymes and components of the microbial 
electron transport system as well as impairing 
some DNA function24,25. Additionally, silver has 
been shown to interact with structural proteins 
and preferentially bind with DNA bases to 
inhibit replication (26,,27). 
 
Therefore, in order to achieve effective control of 
CL, it is pertinent to try other drug-treatment 
modalities which are painless, tolerable, and of 
short duration. Hence the focus of this study 
which compared the efficacy of the topical silver 
nitrate therapy with the antimonials in the 
treatment of CL due to L. tropica in Sokoto, 





MATERIALS AND METHODS 
 
Study location and Participants. The study was 
carried out at 1 Brigade Medical Centre which is 
located in Gingiya military barracks, Sokoto, 
Northwest Nigeria. Established in 1984, the 
medical centre is well staffed, with equipped 
laboratory and provides curative and preventive 
services to the soldiers, their families and the civil 
populace. It is also a designated centre by the 
Sokoto State Ministry of Health and the Nigerian 
Ministry of Defence-US Department of Defense 
(NMOD-USDoD) for the treatment of 
Leishmaniasis and HIV/AID respectively.  
 
Ninety five patients, aged more than 5 years with 
parasitologically confirmed CL lesions were 
recruited for the study. The exclusion criteria 
were pregnancy, breast-feeding mothers, patients 
who had a major surgery in the previous 3 
months, presence of any uncontrolled medical 
condition; anticipated unavailability for follow-
up; and patients allergic to antimonials and silver 
nitrate. 
Ethical issues: The authority of the Medical 
Centre and State’s ethics committee approved the 
study protocol and the consent form. New and 
eligible patients attending the clinic for treatment 
were briefed about the aim and protocol of the 
study. Patients were enrolled in the study after 
an informed consent had been given. All medical 
services provided during the study were free.  
Participant’s Medical History: Prior to the study, 
a detailed medical and personal history of each 
participant was taken. These included the 
duration of symptoms, residence in or travel 
through a possibly leishmaniasis-endemic area, 
history of any existing health condition, 
menstrual and parity history, previous 
treatments and outcome. A general physical 
examination was also carried out to assess the 
location, size of lesions with other characteristics 
such as infiltration, erythema, scaling and 
ulceration. 
Parasitological confirmation: Parasitological 
confirmation of CL was by microscopic 
examination of smear and with RIDASCREEN 
leishmania antibody test kit (R-Biopharm, 
Germany). Scrapings from the lesion edge were 
smeared onto a slide, and the slide was dried, 
fixed with methanol, stained with Giemsa and 
examined under the microscope at x100 
magnification for presence of Leishmania 
amastigotes. For each, patient, 2 slides were 
prepared and all positive slides were rechecked 
and confirmed by at least 2 laboratory scientists. 
For leishmania antibody testing about 3mls of 
whole blood was collected from each participant 
into a clean dry plain blood container and 
allowed to clot. The blood sample was spun with 
a bench centrifuge at 5000rpm for 5 minutes and 
the serum separated into another clean plain 
container and stored frozen prior to testing at -
20⁰C. The samples were tested using Elisa 
leishmania antibody kit (R-Biopharm, Germany), 
using the procedure as described in the manual 
of the kit. 
  
Treatment Procedure 
Sixty patients had a single dose topical silver 
nitrate treatment while 35 had daily 
intramuscular administration of SSG for 21 days 
using the World Health Organization 
recommended treatment for CL (28). For 
intramuscular administration, 20 mg/kg of SSG 
was administered daily (up to a maximum daily 
dose of 850 mg) for 21 days (28). For silver nitrate 
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treatment, the surface of the each lesion was 
cleaned with hydrogen peroxide solution and 
scraped with scalpel blade. The lesion surface 
was mopped with cotton wool to prevent 
bleeding; fine granules of silver nitrate were 
poured into it, covered with water-soaked cotton 
wool and dressed with plaster for 24 hours. After 
24 hours, each lesion was cleaned daily with 
hydrogen peroxide and covered with 
Gentamycin-ointment smeared bandage for 21 
days. Also, in order to prevent secondary 
infection, each patient on the topical silver nitrate 
had 280 mg of intramuscular Gentamycin for 5 
days. Treatment efficacy was measured by the 
percentage of patients cured on 21st and 30th day 
after commencing treatment. “Cure” is defined as 
“the complete re-epithelialization of the CL 
lesion, with no evidence of papules, 
inflammation, or indurations”. 
Data collation and analysis.. The obtained data 
were analyzed using EPI info computer software 
package. The results were displayed in tables and 




A total of 95 patients comprising 74 males 
(77.9%) and 21 females (22.1%) were recruited for 
the study as shown in Table 1. Thirty five 
patients (with a total of 73 lesions) received i.m. 
SSG while 60 (with a total of 79 lesions) received 
topical silver nitrate treatment. In both groups, 
each male patient had an average of 1-2 lesions 
while each female had an average of 2-5 lesions; 
thus implying that the lesions were more among 
females than males. The age range of the patients 
who had intramuscular SSG was 31-42 years 
(mean = 30.5) while that of patients who had 
topical silver nitrate was 16-52 years (mean = 
32.4).  
 
TABLE 1: CHARACTERISTICS OF PATIENTS WITH CUTANEOUS LEISHMANIASIS TREATED WITH 







Intramuscular SSG (%) 
 
Male               Female 
   Topical Silver Nitrate (%) 
 
 Male                          Female 
Total (100%) 
No of Patients 
 




No of Lesions 
 








       30.5 (13 - 42) 
 
        32.4 (16 – 52) 
 
 
Table 2 showed that the nodular/nodular-
ulcerative lesions were the commonest 
(constituting 82.1% and 73.4% in i.m. SSG and 
topical silver nitrate groups respectively). Over 
two-third lesions were located in the upper limbs 
in each treatment category (i.m. SSG=65.8%, 
topical silver nitrate=68.3%).No lesion was seen 
in the groin, perineum or buttocks in both 
treatment categories.   
 
Table 3 showed the cure rate in each category 
after 21st and 30th day of treatment. On day 21, 
Sixty five (82.3%) lesions among patients on 
topical silver nitrate healed completely compared 
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with 4 (5.5%) among those on i.m. SSG. There 
was no improvement in 30 (41%) lesions of 
patients on i.m. SSG compared with 4 (5.1) 
among those on topical silver nitrate. On day 30 
of treatment, 68 (86.1%) lesions among patients 
on topical silver nitrate healed completely as 
compared with only 5 (6.8%) among those on i.m. 
SSG. Also, there was no improvement in 25 
(34.2%) lesions among those on i.m. SSG 
compared with only 1 (1.2%) lesion among those 
on topical silver nitrate. There was a statistically 
significant difference in the cure rate among 
patients on silver nitrate as compared with those 
on i.m. SSG on the 21st and 30th days of 
treatment.(p<0.05). 
 
Apart from complaints of pain at the site of 
injections, which was generally greater in the 
patients who were given i.m SSG, the 
medications were well-tolerated. For each 
patient, the results of the post-treatment 
biochemical and hematological investigations 
were normal. 
 




Characteristics of Lesions 
Type of Treatment  
 
Intramuscular SSG                    Topical Silver nitrate           
      (n = 73 lesions)                             (n = 79 lesions) 
   
   
 
Mean area of lesion and 






Lesion type (% of lesions)                                                                    
  
 






 37(46.8)  
Nodular-ulcerative 28(38.3) 21(26.6) 
Flat-ulcerative 10(13.7) 13(16.4) 
Plaque-like  3(4.1)   8(10.1) 
 
Lesion site (% of lesion) 
Shoulder 





























  5(6.3) 
15(19) 
   3(3.8) 
   
DISCUSSION 
There have been several attempts in the past to 
develop a safe and simply administered drug 
with a broad spectrum of activity against CL. For 
example, high cost and painful injections are 
documented drawbacks of treatment by 
antimonial compounds(14,15). In addition, the 
antimonial drugs have been documented to have 
80-85% cure rate, recurrent clinical signs and 
relapses (16). Thus, the dire need to develop 
effective compounds for the treatment of CL that 
would be economical, ease of administration and 
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could avoid resistance becomes expedient. To 
surmount this challenge, topical/local treatment 
of CL lesions seems a logical alternative. 
Although some forms of topical/local therapy 
have been in long use in endemic areas by 
traditional practitioners, they had little if any 
effect (27).  
 
In this study, more than three-quarter of the 
selected patients were males. The few female 
participants could be attributed to the exclusion 
criteria which included pregnant women and 
breastfeeding mothers. The patients were given 
the option of  choosing a treatment regimen after 
the informed consent had been obtained and this 
accounted for the selection of silver nitrate 
treatment by 60 (63.2%) of the 95 patients. For 
each treatment regimen, it was observed that the 
male patients had an average of 1-2 lesions while 
females had an average of 2-5 lesions; thus 
implying that the lesions were more among 
females than males. The reason(s) for this 
variation cannot be explained since both gender 
were equally exposed to the vector. Further 
research to determine this variation is desirable. 
Also, in both treatment regimen, it was observed 
that over two-third lesions were located in the 
upper limbs (i.m. SSG=65.8%, topical silver 
nitrate=68.3%) and none was seen in the groin, 
perineum or buttocks. This finding implies that 
the exposed parts of the body were more 
accessible to the vector. It is therefore necessary 
to emphasize the use of protective clothes by the 
communities; especially while in the farm (or 
grazing animals); as an important preventive 
measure against the vector bites.    
 
TABLE 3: COMPARISON OF THE CURE RATE AMONG PATIENTS ON INTRAMUSCULAR SSG AND TOPICAL 





Cure Rate IM SSG (%) 
(n=73) 
Topical Silver Nitrate (%) 
       (n=79) 
 P value 
 
Day 21 of 
treatment 
 
Fully healed lesions 
Improved lesions 


























Day 30 of 
treatment 
 
Fully healed lesions 
Improved lesions 



























More than four-fifth (82.3%) of the lesions among 
patients on topical silver nitrate and only 5.5% 
lesions those on i.m. SSG healed completely on 
the  21st day of commencing treatment. By the 
95 
  
30th day, 86.1% of the lesions among those on 
silver nitrate had healed completely as compared 
with only 6.8% among those on i.m. SSG. There 
was a statistically significant difference in the 
cure rate between patients on silver nitrate and 
those on i.m. SSG on the 21st and 30th days of 
treatment.(p<0.05). 
Conclusion: In comparing the efficacy of topical 
silver nitrate and i.m. SSG in the treatment of CL, 
this study has shown that a single dose treatment 
with topical silver nitrate plus topical gentamycin 
(for secondary infections) was more effective. The 
study also highlighted the need to educate the 
community on the use of protective clothing to 
reduce the bite by the vector. The reasons for the 
gender variation in the number of CL lesions 





We are grateful to the management and staff of 1 
Brigade Medical Centre, Gingiya Barracks for 
their facility and cooperation during the period 




1. Mandell GL, Bennett  JE, Dolin. In Mandell, 
Douglas, and Bennett’s Principles and practice of 
infectious diseases. Elsevier, 6th edn. 2005: 2428-
2442. 
 
2. Roberts MTM. Current understandings on the 
immunology of leishmaniasis and recent 
developments in prevention and treatment. Br. 
Med.Bull: 2006; 76: 115–130. 
 
3. Mauel J.. Vaccination Against Leishmania 
Infections. Current drug targets. immune. Endocr. 
Metabol. Disord.2002; 2: 201- 226. 
 
4. World Health Organization. Control of 




5. Davies CR, Kaye P, Croft SL, Sundar S. 
Leishmaniasis: New approaches to disease 
control. BMJ. 2003; 326: 377– 382. 
 
6. Reithinger R, Dujardin JC, Louzir H, Pirmez C, 
Alexander B. and Brooker S. Cutaneous 
Leishmaniasis. Lancet. Infect. Dis. 2007: 581– 596 
 
7. Singh S. New developments in diagnosis of 







8. Desjeux P. The increase in risk factors for 
leishmaniasis worldwide. Trans. R. Soc. Trop. 
Med. Hyg. 2001; 95: 239- 243. 
9. Jelliffe RS. Cutaneous Leishmaniasis in Nigeria 




10. Handmann E. Leishmaniasis: Current status 
of vaccine development. Clin Microbiol Rev. 
2001;14:229–243. 
 
11. Berman JD. Human Leishmaniasis: clinical, 
diagnostic and chemotherapeutic developments 
in the last ten years. Clin Infect Diseases.1997; 
24:684–703. 
 
12. Croft SL, Yardley V. Chemotherapy of 
Leishmaniasis. Curr Pharm Design. 2002; 8:273–
301. 
 
13. Croft SL, Coombs GH. Leishmaniasis—
Current chemotherapy and recent advances in 
the search for novel drugs. Trends Parasitol; 2003; 
19: 502–8. 
 
14. Boelaert M, LeRay D, Van Der Stuyft P. How 
better drugs could change kala-azar control: 
lessons from a cost-effectiveness analysis. Trop 
Med Int Health.2002;7:955–959. 
 
15. Aronon NE, Wortman GW, Jackson JE, Gasser 
RA Jr, Magill JA et al. Safety and efficacy of 
intravenous sodium stibogluconate in the 
treatment of leishmaniasis: recent US military 




16. Bryceson A. A policy for leishmaniasis with 
respect to the prevention and control of drug 
resistance. Trop Med Int Health.2001;6:928–934. 
 
17. Dowlati Y. Cutaneous leishmaniasis: clinical 
aspect. Clin Dermatol; 1996;14: 425–431. 
 
18. Romero GAS, Guerra MVS, Paes MG, Macedo 
VO. Comparison of Cutaneous leishmaniasis due 
to leishmania braziliensis and leismania 
guyanensis in Brazil: Therapeutic response to 
meglumine antimonite. Am J Med Hyg.2001; 
65:456-465. 
 
19. Rojas R, Valderrama L, Valderamma M, 
Varona MX, Quettette M et al. Resistance to 
antimony and treatment failure in human 
leishmaniasis infection. J Infect Dis. 2006;193:1375-
1383. 
20. Lockman Y, Vardy D, Ohayon D, Elon J. The 
failure of traditionally used desert plants to act 
against cutaneous leishmaniasis in experimental 
animals. Annals of Tropical Medicine and 
Parasitology .1991; 85: 499-501. 
 
21. Gunawan C, Teoh WY, Marquis CP, Lifla J, 
Amal R. Reversible antimicrobial 
photoswittching in nanosilver. Small.2009;5 
(3):341-344. 
 
22. Mehrbod P, Motamed N, Tabatabaian M, 
Soleimani Estyar R, Amini E, Shahidi M, 
Tavasoti- Kheiri M. In Vitro Antiviral Effect of 
“Nanosilver” on Influenza Virus. DARU. 2009;17: 
88-93. 
 
23. Trop M, Novak M, Rodl S, Hellbom B, Kroell 
W, Goessler W. Silver-coated dressing acticoat 
caused raised liver enzymes and argyria-like 
symptoms in burn patient. Journal of Trauma. 
2006; 60 (3): 648–652. 
 
24. Mooney EK. Silver dressings [safety and 
efficacy reports]. Plast Reconstr Surg; 2006; 117(2): 
666–669. 
 
25. Poon VK, Burd A. In vitro cytotoxity of silver: 
implication for clinical wound care. Burns; 2004; 
30:140–147. 
 
26. Dunn K, Edwards-Jones V.. The role of 
Acticoat TM with nanocrystalline silver in the 
management of burns. Burns; 2004;30: 81–91. 
 
27. Reyburn, HA. Guide to the treatment of 
cutaneous leishmaniasis. Kabul, Afghanistan: 
World Health Organization. 2000. 
 
 
 
 
 
 
 
 
97 
